Skip to content

Dr. Taya Bezhaeva


taya bezhaeva


“Currently, I am focusing on therapeutic strategies to induce new capillary formation (angiogenesis) and improve the overall quality of the microvasculature in the myocardium. In particular, I study endothelial (dys)function, capillary maturation and leakiness, and vasoconstriction/vasodilation.

For evaluation of therapeutic approaches aiming to maintain or increase cardiac function of the (explanted) heart I use a number of in vivo and in vitro models including myocardial infarction and ex vivo cultured mouse hearts. In my work I apply state-of-the-art imaging techniques such as VEVO-LAZRx photoacoustic imaging, two-photon and light-sheet microscopy to study the therapeutic effects on vascular integrity in 3D.”

Several research lines include:

  • The role of dietary restriction, specifically H2S.H2Sn and its prodrugs for beneficial tissue survival

  • The role of relaxin as a potential target to improve cardiac function

  • Role of 14Q32 microRNAs in angiogenesis, endothelial function and capillary maturation

  • Role of VEGF and related factors

  • The role of maturation increasing factors in preservation of the myocardium

Curriculum Vitae

“I am a dedicated scientist backed by more than 10 years of international research experience in both academic and industrial sectors.

I did my PhD at the Leiden University Medical Centre (LUMC) department of vascular and regenerative medicine, where I was unravelling haemodialysis vascular access failure – a major vascular complication in patients with end-stage renal disease. Obtaining a grant from the Dutch Kidney Foundation facilitated me to join the department of biomedical engineering at the University California, Los Angeles. Here, I was working on in situ engineered replacement of damaged vessels.

After obtaining my PhD, I continued to work as a Postdoctoral Fellow in a consortium between Leiden University and the University of Amsterdam. Under the supervision of dr. Rotmans and prof. Nieuwdorp I was studying the role of gut-microbiome-kidney axis in the progression of diabetic nephropathy.

Driven by my interest in data science and analytics over a short period I joined the life science consultancy team at Elsevier. Sharing expertise in several scientific domains I was in volved in big data harmonization, aiming to accelerate drug discoveries, and identify potential drug and patient safety signals for a number of pharma and academic customers.

Now I work within the RegMed XB consortia that comprises a public-private partnership between governments, health foundations, academic and industrial companies. At the LUMC I work in the vascular surgery group headed by Prof. Quax. We actively collaborate with prof. Goumans at the department of Cell and Chemical Biology, and dr. de Vries at the department of experimental Cardiology.”

Recent publications